Daratumumab

Where the papers sit

11 papers from the last 6 months study daratumumab directly · updated from PubMed 12 Oct 2026

• Frontline Myeloma Therapy

  Dara-VRd is moving beyond VRd as a frontline strategy for transplant-eligible myeloma, with deeper responses and greater minimal residual disease negativity. Economic analyses support the added regimen, but pooled and retrospective data keep infection burden and safety central to treatment selection. CEPHEUS extends MRD-focused evaluation to transplant-ineligible or deferred patients, broadening the target population. The remaining question is whether response gains justify cost and toxicity across risk groups.

  5 papers · 45.5%

• AL Amyloidosis Treatment

  Daratumumab with bortezomib, cyclophosphamide and dexamethasone is becoming a central frontline regimen for AL amyloidosis. The work prioritizes hematologic complete response alongside cardiac and renal recovery, because organ benefit determines prognosis. Chinese real-world data emphasize delayed diagnosis and heterogeneous treatment access, while renal heavy-chain amyloidosis illustrates severe kidney injury. Whether early responses translate uniformly into durable organ survival remains open.

  3 papers · 27.3%

• Others — Myeloma Therapy and Mechanisms

  Frontline and relapsed multiple myeloma regimens pair daratumumab with cyclophosphamide, bortezomib, lenalidomide or dexamethasone. Clinical work centers on induction, consolidation and progression-free survival, including ICd in relapse. A separate mechanistic study places therapeutic antibody–receptor complexes near cholesterol-rich membrane domains, suggesting interest in how membrane organization shapes antibody action. The cluster therefore links treatment selection with early cellular-mechanism work rather than showing a single clinical direction.

  3 papers · 27.3%